IME1 - Understanding the Financial Impacts of 340B Policy Changes on Pharmacy Revenue

Session Description: The 340B Program impacts the finance team both directly and indirectly. This session will delve into the intricate landscape of the 340B Program and its evolving policy dynamics. Besides discussing critical 340B program operational elements like UDS reporting, we will look at how savings calculations will be impacted by recent developments such as the Inflation Reduction Act (IRA) and the removal of the Average Manufacturer Price (AMP) Cap on Medicaid rebates. Health centers face a paradigm shift in drug pricing and reimbursement structures in both their in-house pharmacies and at contract pharmacies. Additionally, alterations in Direct Indirect Remuneration (DIR) fee assessment methodologies further impact pharmacy revenue.

This session serves as a compass, guiding participants through the maze of policy changes to understand their tangible impacts on pharmacy revenue streams. Speakers will unravel the implications of IRA and AMP Cap removal on drug pricing dynamics, providing clarity on navigating the evolving reimbursement landscape. Moreover, attendees will gain invaluable insights into the ramifications of DIR fee assessment modifications, empowering them to understand the reason behind observed reductions in pharmacy point-of-sale payments from certain payers.

Armed with practical knowledge, participants will learn how to conduct comprehensive assessments to gauge the effects of these policies on both pharmacy revenue and the health center budget. Whether you're a Pharmacy Director, CFO, or Board Member, this session equips you with the tools and understanding necessary to adapt your health center budget amidst regulatory transformations in the 340B Program.